跳至主要内容
临床试验/NCT02765581
NCT02765581已完成不适用

Evaluating the Prophylactic Efficacy of Acupuncture for Migraine Without Aura (MWoA) : A Randomized Controlled Trial

Wei Wang1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2016年5月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
150
试验地点
1
主要终点
Change in the number of migraine days

研究概览

简要总结

Acupuncture is commonly used for the prevention of migraine, while the evidence for its efficacy is still uncertain. Current studies have not been able to determine whether the efficacy of acupuncture is due to the actual therapeutic effect of acupuncture, or a result of psychological benefits. To address this issue, we designed a clinical trial to evaluate the prophylactic efficacy of acupuncture for migraine without aura (MWoA). Furthermore, we will evaluate the impact of Chinese medicine factors and psychological factors on the efficacy of acupuncture.

详细描述

This is a multicentre, stratified, randomized, sham-controlled clinical trial. 150 eligible participants will be randomly allocated into verum acupuncture, sham acupuncture, or usual care groups, in a 2:2:1 ratio. The verum acupuncture group will receive twenty verum acupuncture treatments over an eight-week period, while the sham acupuncture group will receive sham acupuncture treatments with non-penetrating needling. Participants assigned to the usual care group are scheduled to receive twenty verum acupuncture treatments for free after waiting 24 weeks. Health education will be provided to participants in the three groups. The primary outcomes will be the changes in the mean number of migraine days and migraine attacks per four-week cycle. The secondary outcomes will be as follows: the proportion of responders, migraine intensity, migraine disability assessment questionnaire, health-related and sleep-related quality of life, the dose of intake of acute medication. Chinese medicine factors will include de qi sensations and Traditional Chinese Medicine (TCM) constitution. Psychological outcomes will include anxiety, depression, personality, expectancy about acupuncture, and doctor-patient relationship. The central randomization and data collection will be conducted by an electronic data management system.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
15 Years 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed as migraine without aura according to the International Classification of Headache Disorders,3rd edition beta version (ICHD-3β);
  • Aged between 15 and 65 years old, with initial onset of migraines before the age of 50 years; and
  • Experienced migraine attacks for at least 1 year; and
  • Experienced migraine attacks with 2-8 times per month during the last 3 months and baseline period, and the duration of migraine attacks lasting 4-72h without intake of acute drugs or at least 2h with intake of acute drugs; and
  • the mean headache Visual Analogue Scale (VAS) scores 4-8 at baseline; and
  • Had not taken any acupuncture treatment before study entry; and
  • Able to complete the baseline headache diary; and
  • Able to signing a informed consent.

排除标准

  • Tension-type headache, cluster headache, and other primary headache disorders, secondary headache disorders, neuralgia of the face or head; and
  • Combined with cardiovascular, liver, kidney, gastrointestinal tract, blood system and other serious primary diseases affecting the implementation of treatment programs, or combined with epilepsy, Parkinson or other nervous system diseases; and
  • Patients with severe mental illness, such as severe anxiety and depression; and
  • Pregnant women, women in lactation, and those planning to become pregnant; and
  • Participation in other clinical trials; and
  • Illiterate, or patients unable to read and understand scales;
  • Have experience of acupuncture.

研究组 & 干预措施

Verum acupuncture (VA)

Experimental

Participants will be treated by verum acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.

干预措施: Verum acupuncture (Device)

Usual care (UA)

Placebo Comparator

Participants will undergo a clinical interview once a month, complete the headache diary assessment, have counseling and health education, and rescue medication if necessary. In addition, they will be scheduled to receive 20 sessions of verum acupuncture treatments for free after a waiting period of 24 weeks.

干预措施: Usual care (Behavioral)

Verum acupuncture (VA)

Experimental

Participants will be treated by verum acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.

干预措施: Usual care (Behavioral)

Sham acupuncture (SA)

Sham Comparator

Participants will be treated by sham acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.

干预措施: Sham acupuncture (Device)

Sham acupuncture (SA)

Sham Comparator

Participants will be treated by sham acupuncture and usual care. They will be treated every other day to fulfill a 10-session treatment course, and another course will begin after resting 9 days. Each acupuncture treatment session for patients will be 30 minutes in duration.

干预措施: Usual care (Behavioral)

结局指标

主要结局

Change in the number of migraine days

时间窗: At baseline (four weeks before randomization), weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.

The changes in the mean number of migraine days per 4-week cycle

Change in the frequency of migraine attacks

时间窗: At baseline (four weeks before randomization), weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.

The changes in the mean number of migraine attacks per 4-week cycle

次要结局

  • Change in 36-Item Short-Form Health Survey(SF-36).(At baseline (four weeks before randomization), weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.)
  • The proportion of responders(At weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.)
  • Change in visual analogue scale(At baseline (four weeks before randomization), weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.)
  • Change in the dose of intake of acute medication.(At baseline (four weeks before randomization), weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.)
  • Change in Migraine Disability Assessment questionnaire(MIDAS).(At baseline (four weeks before randomization), weeks 5-8 after randomization and weeks 17-20 after randomization.)
  • Change in Short-Form McGill Pain Questionnaire 2 (SF-MPQ-2).(At baseline (four weeks before randomization), weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.)
  • Change in Migraine-Specific Quality of Life Questionnaire(MSQ) Version 2.1.(At baseline (four weeks before randomization), weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.)
  • Change in Pittsburgh Sleep Quality Index(PSQI).(At baseline (four weeks before randomization), weeks 1-4 after randomization, weeks 5-8 after randomization, weeks 9-12 after randomization, weeks 13-16 after randomization, and weeks 17-20 after randomization.)

研究者

发起方
Wei Wang
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Wei Wang

Professor

Huazhong University of Science and Technology

研究点 (1)

Loading locations...

相似试验